Work

Abstract 3160: Sustained MAPK activation as a mechanism of resistance to osimertinib plus selumetinib in models of EGFR-mutant cancer

Year: 2017

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2017-3160

Authors: David Westover, Catherine B. Meador, Eiki Ichihara, Hayden F. Byrd, Cath Eberlein, Yingjun Yan, Darren A. Cross, Christine M. Lovly

Institutions: Vanderbilt-Ingram Cancer Center, AstraZeneca (United Kingdom)

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2741767006

Cites:

Cited by:

Related to: 10